DIRS.INFO The most relevant business & tech news

☆ Judge extends deadline in lawsuit seeking to pull abortion pill mifepristone from U.S. until Feb. 24
▼ + stars: | 2023-02-10 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

A federal judge in Texas has extended until Feb. 24 the deadline in a lawsuit seeking to overturn the Food and Drug Administration's approval of the abortion pill. The abortion rights group NARAL Pro-Choice America, in an analysis published Friday, said 40 million women would lose access to the abortion pill if the Alliance for Hippocratic Medicine succeeds and mifepristone is effectively banned. It would also weaken the FDA's drug approval powers and hinder drug development by creating regulatory uncertainty in the marketplace. Two separate lawsuits are also seeking to overturn state restrictions on mifepristone, arguing that they conflict with FDA regulations. Republican attorneys general in 20 states also recently warned CVS and Walgreens against mailing the abortion pill in their states, indicating that they would take legal action.

In one, generic mifepristone maker GenBioPro is asking a federal judge to block West Virginia, which has a near-total abortion ban, from prohibiting sales of the pills. The state is one of 16 that allow abortion under some circumstances, but impose additional restrictions on mifepristone that make it harder to access. WHAT WOULD HAPPEN IF THE TEXAS PLAINTIFFS WIN? IS A WIN BY TEXAS PLAINTIFFS LIKELY? The West Virginia lawsuit makes a more novel legal argument, since West Virginia's abortion ban applies to all abortions and does not specifically regulate mifepristone.

The states filed a complaint in a federal court in Amarillo, Texas, on Thursday arguing that the rule finalized in November will lead many retirement plans to focus on a social agenda rather than long-term financial stability for investors. The rule, which takes effect on Monday, reverses restrictions on socially conscious investing that were adopted by the Trump administration. The states in Thursday's lawsuit said the new rule fails to justify the departure from Trump-era regulations, in violation of the federal law governing rulemaking. And, the states said, it violates the U.S. law that regulates employee benefit plans by failing to protect retirement assets. The case is Utah v. Walsh, U.S. District Court for the Northern District of Texas, No.

☆ The FDA's power to approve drugs faces sweeping challenge in lawsuit seeking to pull abortion pill from U.S. market
▼ + stars: | 2023-01-24 | by ( Spencer Kimball | ) www.cnbc.com time to read: +7 min

The Alliance for Hippocratic Medicine asked a federal district court in Dallas late last year to declare the FDA approval unlawful and completely remove the abortion pill from the U.S. market. If the lawsuit prevails, women across the U.S. would lose access, at least temporarily, to the most commonly used abortion method. Judge Matthew Kacsmaryk is hearing the challenge to the FDA's approval of the abortion pill. Lawrence Gostin, an expert on public health law at Georgetown Law, said it would be "highly irresponsible" and "reckless" for a judge to overturn the FDA approval of mifepristone. Under federal law, lawsuits against the U.S. government must be filed within six years of an agency action.

Medication abortion has drawn increasing attention since the U.S. Supreme Court last June overturned its landmark 1973 Roe v. Wade decision that had legalized abortion nationwide. Nearly all abortions, including medication abortions, are now banned in 12 states, and 16 states that permit some abortions also had laws restricting medication abortion as of November, according to the Guttmacher Institute, a research group that supports abortion rights. "The FDA, by approving chemical abortion drugs for home use, puts a woman or girl's life at risk." In its court filing, the FDA said there was no basis for second-guessing the FDA's judgment. The FDA said that pulling the drug would force patients seeking abortions in many cases to undergo unnecessary and more invasive surgical abortion.

☆ Federal judge temporarily blocks Biden from ending Trump-era 'Remain in Mexico' policy
▼ + stars: | 2022-12-16 | by ( Zoë Richards | Zoë Richards Is The Evening Politics Reporter For Nbc News. | ) www.nbcnews.com time to read: +1 min

A federal judge on Thursday temporarily blocked the Biden administration from ending a Trump-era policy designed to restrict immigration at the southern border. The Supreme Court said in a 5-4 ruling in June that the Biden administration had acted properly in seeking to end the policy, reversing a federal appeals court ruling that rejected a fresh attempt to end the policy in October 2021. The administration was previously forced to reinstate the policy after Texas and Missouri sued. Texas Attorney General Ken Paxton, who filed suit to block the policy from being lifted, praised the judge's order on Twitter. Immigrant rights groups and opponents of "Remain in Mexico," which is separate from another Trump-era border policy known as Title 42, say it denies people the right to seek protection in the U.S. and forces them to face potentially dangerous circumstances as they await asylum.

Nov 11 (Reuters) - A federal judge in Texas ruled on Friday that President Joe Biden's administration had wrongly interpreted an Obamacare provision as barring health care providers from discriminating against gay and transgender people. U.S. District Judge Matthew Kacsmaryk in Amarillo ruled that a landmark U.S. Supreme Court decision in 2020 holding that a law barring workplace discrimination protects gay and transgender employees did not apply to the healthcare law. "Title IX's ordinary public meaning remains intact until changed by Congress, or perhaps the Supreme Court," Kacsmaryk wrote. The Obama administration introduced rules in 2016 that made clear that LGBT people would be protected under the healthcare discrimination provision. In June, the Biden administration proposed a rule to once again enshrine such protections.

Search resuls for: "Matthew Kacsmaryk"

7 mentions found